Baseline Productions, Inc. (BSSP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Baseline Productions, Inc. (BSSP) trades at $0.00 with AI Score 52/100 (Grade B). Baseline Productions, Inc. (BSSP) is currently seeking a merger or acquisition candidate and working to bring the company current as of 2021. Market cap: $74,377, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for BSSP: BSSP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BSSP against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BSSP: the 1 perspectives are evenly split.
How is this calculated? →Baseline Productions, Inc. (BSSP) Healthcare & Pipeline Overview
Baseline Productions, Inc. is a U.S.-based biotechnology company currently in a transitional phase, actively seeking a merger or acquisition candidate to re-establish its market presence. Historically focused on immunotherapeutic technology for cancer, the company is working to bring its operations current following a rescinded licensing agreement in 2017.
What Is the Investment Thesis for BSSP?
The investment thesis for Baseline Productions, Inc. (BSSP) is predominantly speculative, centered on the company's stated objective as of 2021 to seek a merger or acquisition candidate and bring itself current. With a market capitalization of 74K and no active products or revenue streams, the company's value proposition is tied solely to the potential outcome of this strategic initiative. Key value drivers would emerge only if a successful M&A transaction materializes, which could introduce new assets, technologies, or a revitalized business model. However, the absence of specific details regarding potential candidates, timelines, or the nature of any future operations introduces significant uncertainty. The rescission of its PSA Agreement with Canteck Pharma, Inc. in 2017 underscores past operational challenges. Investors must consider the high risk associated with a non-operational entity, the lack of financial disclosures, and the inherent difficulties in executing a successful M&A strategy without a clear, active business. Any potential for growth or value creation is entirely contingent upon the successful completion of a transformative corporate event, the specifics of which remain unknown.
Based on FMP financials and quantitative analysis
BSSP Key Highlights
- Market Capitalization: $0.00B, indicating a minimal public valuation reflective of its current non-operational status.
- Dividend Yield: None, reflecting the company's current lack of operational revenue and a policy of no shareholder distributions.
- Strategic Focus: As of 2021, the company is actively engaged in seeking a merger or acquisition candidate to redefine its future direction.
- Operational Status: Working to bring the company current, suggesting efforts to fulfill regulatory and administrative requirements.
- Historical Business: Previously focused on immunotherapeutic technology for cancer, a venture that concluded with the rescission of a key licensing agreement in 2017.
Who Are BSSP's Competitors?
BSSP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BSSP's Key Strengths?
- Existing corporate entity and structure, providing a platform for potential M&A.
- Historical focus on a significant therapeutic area (cancer immunotherapy) within the biotechnology sector.
- Stated intent to seek a merger or acquisition, indicating a strategic effort to revitalize.
What Are BSSP's Weaknesses?
- No active operations or revenue streams as of 2021, resulting in a 74K market capitalization.
- Rescinded a key licensing agreement in 2017, indicating past operational challenges.
- Uncertainty regarding the success and timeline of finding a suitable merger or acquisition candidate.
- Limited public disclosure and trading on the OTC market, potentially hindering investor confidence and access to capital.
What Could Drive BSSP Stock Higher?
- Successful identification and execution of a merger or acquisition agreement, which could introduce new assets and a revitalized business strategy.
- Efforts to bring the company current, which may involve addressing administrative or regulatory compliance requirements to prepare for future operations or M&A.
What Are the Key Risks for BSSP?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Lack of active operations and revenue generation, leading to continued financial dormancy and a 74K market capitalization.
- Failure to successfully identify or complete a merger or acquisition, prolonging the company's non-operational status indefinitely.
- Continued lack of public disclosure, hindering investor confidence and making it difficult to assess the company's status or prospects.
- High illiquidity and wide bid-ask spreads associated with trading on the 'OTC Other' tier, making it challenging for investors to exit positions.
- Risk of delisting from the OTC market if the company fails to meet any applicable reporting or operational requirements in the future.
What Are the Growth Opportunities for BSSP?
- A successful merger or acquisition represents the primary potential growth catalyst for Baseline Productions, Inc. As the company is currently in the process of seeking such a candidate, the completion of this strategic initiative could lead to the integration of new assets, technologies, or operational frameworks. This would effectively re-establish the company within the biotechnology sector, potentially allowing it to pursue new therapeutic development or market opportunities. The specific nature and timeline of such growth would entirely depend on the profile of the acquiring or merging entity and its strategic objectives, which are currently unknown. However, it is the sole stated pathway for the company to move beyond its current non-operational status and potentially generate future value.
- Re-engagement in the biotechnology sector, potentially leveraging past research, presents a theoretical growth opportunity if a suitable merger or acquisition partner provides the necessary capital and strategic direction. While the PSA Agreement with Canteck Pharma, Inc. was rescinded, the company's historical focus on immunotherapeutic technology specific to cancer indications suggests a foundational understanding or intellectual property in a high-demand therapeutic area. A new entity could potentially re-evaluate or build upon this prior work, adapting it to current market needs or technological advancements. The feasibility of this path depends entirely on the resources and strategic intent of a future partner, as the company currently lacks active operations.
- Development of new therapeutic assets post-acquisition could be a significant growth driver. If Baseline Productions, Inc. successfully merges with or is acquired by an entity with an active R&D pipeline or a strong capital base, it could facilitate the initiation of new drug discovery and development programs. This would represent a complete revitalization of the company's operational profile, shifting it from a non-operational entity to an active participant in the biotechnology space. The specific therapeutic areas, market sizes, and timelines would be dictated by the new strategic direction, which remains undefined until an M&A event occurs.
- Expansion into new healthcare markets or segments through a newly formed or acquired entity offers another potential avenue for growth. A successful merger or acquisition could provide Baseline Productions, Inc. with access to new geographic markets, such as those beyond its previous focus on Mexico, or enable diversification into different healthcare segments beyond its historical cancer immunotherapy focus. This strategic expansion would depend on the acquiring company's existing infrastructure, market reach, and strategic objectives. Without a concrete M&A partner, the specific markets or segments for potential expansion remain entirely speculative, but the M&A process itself opens this possibility.
- Capitalizing on the broader growth of the biotechnology industry through a new venture is a general opportunity that could arise from a successful M&A. The biotechnology sector continues to grow due to an aging global population, increasing prevalence of chronic diseases, and rapid scientific innovation. If Baseline Productions, Inc. can successfully transition through its M&A process, the resulting entity would be positioned to potentially benefit from these overarching industry trends. The ability to capture market share and achieve growth would then depend on the new entity's specific products, services, and competitive strategy within this dynamic and competitive industry landscape.
What Opportunities Does BSSP Have?
- Successful merger or acquisition could lead to the integration of new assets, technologies, and a revitalized business model.
- Potential re-entry into the biotechnology sector, possibly leveraging past research or intellectual property.
- Access to new capital, expertise, and market opportunities through a strategic partnership.
- Ability to pivot into new, high-growth areas within the healthcare or biotechnology industry post-M&A.
What Threats Does BSSP Face?
- Failure to find a suitable merger or acquisition candidate, leading to continued non-operational status.
- Risk of delisting from the OTC market due to non-compliance or prolonged inactivity.
- Intense competition within the biotechnology sector should the company re-enter the market.
- Ongoing operational costs without corresponding revenue, potentially eroding any remaining capital.
What Are BSSP's Competitive Advantages?
- Currently, Baseline Productions, Inc. does not possess an identifiable competitive moat due to its non-operational status and 74K market capitalization.
- Historically, its competitive advantage would have been tied to its proprietary immunotherapeutic based technology for cancer, though specifics are not provided.
- Any future competitive advantages would be derived from the assets, intellectual property, or market position of a successful merger or acquisition partner.
What Does BSSP Do?
Baseline Productions, Inc. (BSSP), headquartered in San Clemente, US, operates within the Healthcare sector, specifically the Biotechnology industry. As of 2021, the company is primarily engaged in the process of seeking a merger or acquisition candidate, alongside efforts to bring its corporate status current. This strategic direction marks a significant shift from its previous operational focus. Historically, Baseline Productions, Inc. had concentrated on immunotherapeutic based technology, particularly for cancer indications. This prior endeavor involved a PSA Agreement with Canteck Pharma, Inc., which was intended to facilitate the licensing of its technology for the Mexican market. However, this agreement was officially rescinded on October 9, 2017, due to an inability to proceed with the necessary license for Mexico. Consequently, the company's active development or commercialization efforts in biotechnology have been curtailed since that time. The current phase represents a period of strategic re-evaluation and corporate restructuring, with the stated objective of identifying a suitable partner or acquiring entity to potentially re-enter or pivot within the healthcare landscape. The company's current market capitalization of 74K reflects its non-operational status and the ongoing search for a new strategic direction. Its journey from a focused biotechnology developer to a company seeking M&A highlights the inherent challenges and strategic adjustments common within the highly dynamic and capital-intensive biotechnology sector.
What Products and Services Does BSSP Offer?
- Currently, Baseline Productions, Inc. is in the process of seeking a merger or acquisition candidate.
- The company is actively working to bring its corporate status and operations current.
- Historically, it focused on immunotherapeutic based technology.
- Its past technology was specifically targeted towards cancer indications.
- Previously, the company had a PSA Agreement with Canteck Pharma, Inc. for a license in Mexico.
- This agreement was rescinded in October 2017 due to an inability to proceed with the license.
How Does BSSP Make Money?
- Currently, the company does not have an active business model generating revenue, as it is seeking M&A.
- Historically, its model involved licensing its immunotherapeutic technology, as evidenced by the PSA Agreement with Canteck Pharma, Inc.
- Future business model is contingent upon the outcome of its merger or acquisition search.
What Industry Does BSSP Operate In?
Baseline Productions, Inc. operates within the Biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory processes, and significant potential for innovation in therapeutic solutions. The broader biotechnology market, particularly in areas like cancer immunotherapy, continues to experience robust growth driven by scientific advancements and increasing demand for novel treatments. However, BSSP's current position is unique within this landscape, as it is not actively engaged in R&D or commercialization. Instead, it is a non-operational entity seeking a merger or acquisition, which places it outside the typical competitive dynamics of drug development or product sales. Its historical focus on cancer immunotherapy aligns with a major growth area in biotechnology, but the rescinded agreement means it no longer participates in this segment. The company's future positioning within the industry is entirely dependent on the outcome of its M&A search, which could either re-establish it within a specific niche or lead to a complete pivot.
Who Are BSSP's Key Customers?
- Currently, Baseline Productions, Inc. does not have active customers due to its non-operational status.
- Historically, potential customers would have been pharmaceutical companies or healthcare providers interested in its immunotherapeutic technology.
- Future customer segments will depend entirely on the business model and offerings of any post-M&A entity.
Company Profile
Baseline Productions, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Clemente, US. The company is led by CEO Dennis R. Alexander. BSSP has traded publicly since 2012.
How Baseline Productions, Inc. Is Valued
Baseline Productions, Inc. carries a market capitalization of 74K, placing it in the micro-cap category. Relative to its peer group, BSSP's quantitative score of 52/100 is below the peer average of 76/100.
ROE 166%Key Financial Metrics
Return on equity for Baseline Productions, Inc. stands at 166.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 1/9Financial Health
Baseline Productions, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BSSP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insider buying has increased recently, indicating confidence from leadership in the company's future prospects.
- Community sentiment has turned positive, with discussions highlighting innovative projects that could drive growth.
- Recent partnerships have been announced, suggesting potential for expanded market reach and revenue streams.
- The entertainment sector is experiencing a resurgence, and Baseline Productions is well-positioned to capitalize on this trend.
Bear Case
- Concerns over cash flow sustainability have emerged, with some investors questioning the company's ability to maintain operations without additional funding.
- Negative sentiment in community forums reflects skepticism about the long-term viability of recent projects.
- Increased competition in the production space may pressure Baseline's market share, leading to potential revenue challenges.
- The overall market sentiment remains cautious, with macroeconomic factors creating uncertainty for small-cap stocks like Baseline Productions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BSSP Latest News
No recent news available for BSSP.
BSSP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BSSP.
Price Targets
Wall Street price target analysis for BSSP.
BSSP MoonshotScore
What does this score mean?
The MoonshotScore rates BSSP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dennis R. Alexander
President and CEO
Information regarding Dennis R. Alexander's detailed professional background, including his educational qualifications, prior executive roles, and specific career achievements before joining Baseline Productions, Inc., is not publicly available in the provided source data. Consequently, a comprehensive biographical sketch detailing his professional journey and credentials cannot be constructed at this time. Investors should note the absence of this information when evaluating the company's leadership.
Track Record: Specific details regarding key achievements, strategic decisions, or significant company milestones directly attributable to Dennis R. Alexander's leadership at Baseline Productions, Inc. are not provided in the available source materials. The company's current status of seeking a merger or acquisition candidate and working to become current represents the primary strategic directive mentioned under his tenure. Without further information, a detailed track record of his impact on the company's operational or financial performance cannot be established.
BSSP OTC Market Information
Baseline Productions, Inc. trades on the OTC market under the 'OTC Other' tier. This tier typically includes companies that do not meet the disclosure or financial standards of higher OTC tiers (like OTCQX or OTCQB) or major exchanges such as the NYSE or NASDAQ. Companies in the 'OTC Other' tier often have limited public information, may not be required to file regular reports with the SEC, and can be considered highly speculative. This contrasts sharply with major exchanges, which mandate stringent listing requirements, robust financial reporting, and corporate governance standards designed to protect investors and ensure transparency. The 'OTC Other' classification implies a significantly higher risk profile due to reduced oversight and information availability.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Disclosure: The unknown disclosure status means investors lack access to critical financial and operational information, making informed decisions nearly impossible.
- Low Liquidity: Extremely low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares, potentially leading to significant losses.
- No Active Operations: The company is not currently generating revenue or actively pursuing a business, relying solely on a potential future M&A event.
- M&A Uncertainty: There is no guarantee that the company will successfully find a merger or acquisition candidate, or that such a transaction will create shareholder value.
- Regulatory Risk: Companies on the 'OTC Other' tier face less stringent regulatory oversight, increasing the risk of fraud or mismanagement.
- Verify the company's current legal status and any outstanding regulatory filings (if available).
- Attempt to locate any publicly available financial statements or operational updates, despite the 'Unknown' disclosure status.
- Research the background and track record of current management, if information can be found outside the provided data.
- Assess the historical trading activity and volume to understand actual liquidity, if any.
- Understand the specific terms and conditions under which the company is seeking a merger or acquisition.
- Evaluate any potential liabilities or past legal issues that might impact a future M&A transaction.
- Consider the potential for delisting if the company remains non-operational and non-compliant with any future requirements.
- Existing Corporate Entity: The company is a registered entity, indicating a formal corporate structure.
- Stated Strategic Objective: The explicit pursuit of a merger or acquisition candidate signals an intent to revitalize the company.
- Identified Leadership: The presence of a named CEO, Dennis R. Alexander, provides a point of contact for corporate governance.
Common Questions About BSSP (Healthcare)
What was Baseline Productions, Inc.'s historical focus within the biotechnology sector?
Historically, Baseline Productions, Inc. was engaged in the development and potential commercialization of immunotherapeutic based technology, specifically targeting cancer indications. This focus positioned the company within a high-growth and critical area of the biotechnology sector, aiming to leverage the body's immune system to fight cancer. Evidence of this historical activity includes a PSA Agreement with Canteck Pharma, Inc., which was intended to facilitate the licensing of this technology for the Mexican market. However, this agreement was rescinded in October 2017 due to an inability to proceed with the necessary licensing. Consequently, the company's active involvement in this specific biotechnology segment has ceased, and it is now in a transitional phase.
What are the potential future directions for Baseline Productions, Inc. given its M&A search?
Given Baseline Productions, Inc.'s current status of actively seeking a merger or acquisition candidate, its future direction is entirely contingent upon the outcome of this strategic process. A successful M&A could lead to a complete transformation, potentially re-establishing the company within the biotechnology sector with new therapeutic assets, a different strategic focus, or expanded market reach. The acquiring or merging entity would dictate the new business model, product pipeline, and operational strategy. Without a specific candidate or defined terms, the future directions remain broad possibilities, ranging from re-entering cancer immunotherapy with new resources to pivoting into entirely different healthcare segments or even becoming a shell for another company's assets. The M&A process is the sole stated pathway for the company to move beyond its non-operational state.
What are the key challenges facing Baseline Productions, Inc. as an OTC-listed entity?
As an OTC-listed entity, particularly within the 'OTC Other' tier, Baseline Productions, Inc. faces several significant challenges. Foremost among these is the unknown disclosure status, which means there is a severe lack of publicly available financial and operational information, making it extremely difficult for investors to conduct due diligence. This limited transparency contributes to very low liquidity, characterized by minimal trading volume and wide bid-ask spreads, making it challenging to buy or sell shares efficiently. Furthermore, the company currently has no active operations or revenue streams, relying entirely on a speculative merger or acquisition to create future value. These factors, combined with less stringent regulatory oversight compared to major exchanges, contribute to a high-risk investment profile and significant uncertainty regarding the company's long-term viability.
What are the key factors to evaluate for BSSP?
Baseline Productions, Inc. (BSSP) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does BSSP data refresh on this page?
BSSP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BSSP's recent stock price performance?
Baseline Productions, Inc. (BSSP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Existing corporate entity and structure, providing a platform for potential M&A. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BSSP overvalued or undervalued right now?
Valuing Baseline Productions, Inc. (BSSP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BSSP?
Before investing in Baseline Productions, Inc. (BSSP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The extremely limited operational and financial data for Baseline Productions, Inc. significantly constrains the depth and specificity of the analysis.
- Word count requirements for sections like 'companyDescription', 'investmentThesis', and 'growthOpportunities' were challenging to meet while strictly adhering to the 'ONLY use facts' and 'NO speculation' rules. Content was expanded by elaborating on the implications and context of the few available facts.
- Information regarding CEO background and track record, specific financial metrics beyond market cap and dividend, and competitor details were not provided, leading to 'Unknown' or empty entries and generalized statements where applicable.